drug-development-guide

Drug Development Guide

A comprehensive skill covering the drug development pipeline from target identification through regulatory approval. Designed for pharmaceutical researchers, medicinal chemists, and clinical scientists conducting academic or industry research.

Drug Discovery Pipeline Overview

Target ID -> Hit Finding -> Lead Optimization -> Preclinical -> Phase I -> Phase II -> Phase III -> Regulatory Filing
  (1-2 yr)    (1-2 yr)      (1-3 yr)            (1-2 yr)      (1 yr)     (2 yr)      (3 yr)       (1-2 yr)

Total timeline: ~10-15 years | Success rate: ~5-10% from Phase I to approval
Estimated cost: $1.3B-$2.8B per approved drug (DiMasi et al., 2016)

Target Identification and Validation

Computational Target Discovery

import pandas as pd
from scipy import stats

def differential_expression_analysis(expression_data: pd.DataFrame,
                                      disease_group: list[str],
                                      control_group: list[str],
                                      fdr_threshold: float = 0.05) -> pd.DataFrame:
    """
    Identify differentially expressed genes as potential drug targets.

    Args:
        expression_data: Gene x Sample expression matrix
        disease_group: Sample IDs in disease condition
        control_group: Sample IDs in control condition
        fdr_threshold: False discovery rate threshold
    """
    results = []
    for gene in expression_data.index:
        disease_vals = expression_data.loc[gene, disease_group]
        control_vals = expression_data.loc[gene, control_group]
        t_stat, p_value = stats.ttest_ind(disease_vals, control_vals)
        fold_change = disease_vals.mean() / (control_vals.mean() + 1e-10)
        results.append({
            'gene': gene,
            'fold_change': fold_change,
            'log2_fc': np.log2(abs(fold_change) + 1e-10),
            'p_value': p_value,
            't_statistic': t_stat
        })

    df = pd.DataFrame(results)
    # Benjamini-Hochberg FDR correction
    from statsmodels.stats.multitest import multipletests
    df['fdr'] = multipletests(df['p_value'], method='fdr_bh')[1]
    df['significant'] = df['fdr'] < fdr_threshold
    return df.sort_values('fdr')

Target Validation Criteria

A robust drug target should satisfy multiple criteria:

| Criterion | Method | Evidence Strength |

|-----------|--------|------------------|

| Genetic association | GWAS, Mendelian randomization | Strong |

| Expression in disease tissue | RNA-seq, immunohistochemistry | Moderate |

| Functional role | CRISPR knockout, siRNA | Strong |

| Druggability | Structural analysis, binding pockets | Essential |

| Safety (anti-target) | Phenotype of loss-of-function mutations | Essential |

Lead Optimization

ADMET Property Prediction

Assess absorption, distribution, metabolism, excretion, and toxicity early:

def lipinski_rule_of_five(molecular_weight: float, logp: float,
                           hbd: int, hba: int) -> dict:
    """
    Evaluate Lipinski's Rule of Five for oral bioavailability.

    Args:
        molecular_weight: Molecular weight in Da
        logp: Calculated LogP (lipophilicity)
        hbd: Number of hydrogen bond donors
        hba: Number of hydrogen bond acceptors
    """
    violations = 0
    details = []

    if molecular_weight > 500:
        violations += 1
        details.append(f"MW {molecular_weight} > 500")
    if logp > 5:
        violations += 1
        details.append(f"LogP {logp} > 5")
    if hbd > 5:
        violations += 1
        details.append(f"HBD {hbd} > 5")
    if hba > 10:
        violations += 1
        details.append(f"HBA {hba} > 10")

    return {
        'violations': violations,
        'passes': violations <= 1,
        'details': details,
        'assessment': 'Likely orally bioavailable' if violations <= 1
                      else 'Poor oral bioavailability expected'
    }

Pharmacokinetics Modeling

Compartmental PK Analysis

import numpy as np
from scipy.optimize import curve_fit

def one_compartment_iv(t, dose, V, CL):
    """One-compartment IV bolus model."""
    k_el = CL / V
    return (dose / V) * np.exp(-k_el * t)

def compute_pk_parameters(time_points: np.ndarray,
                           concentrations: np.ndarray,
                           dose: float) -> dict:
    """
    Fit one-compartment model and derive PK parameters.
    """
    popt, pcov = curve_fit(
        lambda t, V, CL: one_compartment_iv(t, dose, V, CL),
        time_points, concentrations,
        p0=[10, 1], bounds=(0, [1000, 100])
    )
    V, CL = popt
    t_half = 0.693 * V / CL
    auc = dose / CL

    return {
        'volume_of_distribution_L': round(V, 2),
        'clearance_L_hr': round(CL, 2),
        'half_life_hr': round(t_half, 2),
        'AUC_mg_hr_L': round(auc, 2)
    }

Clinical Trial Design

Phase Selection and Endpoints

| Phase | Primary Goal | Typical N | Key Endpoints |

|-------|-------------|-----------|---------------|

| Phase I | Safety, dose finding | 20-80 | MTD, DLT, PK |

| Phase II | Efficacy signal | 100-300 | ORR, PFS, biomarkers |

| Phase III | Confirmatory efficacy | 300-3000 | OS, PFS, PROs |

| Phase IV | Post-marketing surveillance | 1000+ | ADRs, real-world effectiveness |

Always pre-register clinical trials on ClinicalTrials.gov and follow CONSORT guidelines for reporting. Use adaptive trial designs (e.g., Bayesian adaptive randomization, seamless Phase II/III) when appropriate to improve efficiency.

References

• DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016). Innovation in the pharmaceutical industry. Journal of Health Economics, 47, 20-33.
• Lipinski, C. A. (2004). Lead- and drug-like compounds. Advanced Drug Delivery Reviews, 56(3), 215-217.